In a heated congressional hearing, Senator Bernie Sanders and other lawmakers pressed Novo Nordisk's CEO regarding the exorbitant prices of the weight-loss drugs Ozempic and Wegovy. Criticism was directed at the company's pricing strategy, described by Sanders as driven by 'greed.' Senators sought explanations for the stark price differences compared to other countries, with the CEO attributing high costs primarily to insurance companies and U.S. healthcare complexities. Amidst the scrutiny, there are discussions of potential negotiations to lower drug prices, and analysts suggest market forces could eventually make obesity drugs more affordable for American consumers.